| 任保瑞 朱彦君 王桂洪 伍青 张希东 吴科 刘颖汇.Ⅰ-ⅢA期非小细胞肺癌KRAS基因突变与ERCC1、TYMS mRNA 表达水平的相关研究[J].,2016,16(10):1833-1837 |
| Ⅰ-ⅢA期非小细胞肺癌KRAS基因突变与ERCC1、TYMS mRNA 表达水平的相关研究 |
| Correlation of KRAS Mutations with the mRNA Expression Levels ofERCC1 and TYMS in StageⅠto ⅢA Non-small Cell Lung Cancer |
| |
| DOI： |
| 中文关键词: 非小细胞肺癌 KRAS 核苷酸切除修复交叉互补基因1 胸苷酸合成酶 化疗 |
| 英文关键词: Non-small cell lung cancer KRAS ERCC1 TYMS Chemotherapy |
| 基金项目:卫生部医药卫生科技发展研究中心基金项目（W2011FAI13） |
|
| 摘要点击次数: 757 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨Ⅰ-ⅢA 期非小细胞肺癌（NSCLC）KRAS基因突变与核苷酸切除修复交叉互补基因1（ERCC1）、胸苷酸合成酶
（TYMS）mRNA 表达水平的相关性及其与患者临床病理特征的关系。方法：收集空军总医院胸外科2010 年06 月至2014 年10 月
符合入组条件的Ⅰ-ⅢA期NSCLC 患者69 例，肺癌组织标本均为手术中切取，KRAS 基因突变应用xTAG- 液相芯片法检测，
ERCC1、TYMS mRNA 表达水平应用分支DNA-液相芯片法检测。结果：在69 例检测样本中，共有13例存在KRAS 基因突变，突
变率为18.8%（13/69）；男性患者中KRAS基因突变率（29.3%，12/41）较女性患者（3.6%，1/28）高（P=0.007）。ERCC1 mRNA的表达
水平与病理类型、吸烟史、有无淋巴结转移、临床TNM 分期相关（P<0.05），TYMS mRNA 表达水平与患者各临床病理特征无关
（P>0.05）。KRAS 突变型患者ERCC1 mRNA表达水平比KRAS野生型患者高（P<0.05），KRAS 基因突变与TYMS mRNA 表达水
平无关（P>0.05）。结论：在Ⅰ-ⅢA 期NSCLC 患者中，男性患者更容易发生KRAS突变。KRAS突变型患者可能不能从铂类化疗药
物中受益，有利于指导早中期NSCLC 患者术后的个体化治疗。 |
| 英文摘要: |
| Objective:To investigate whether KRAS gene mutations are correlated with the mRNA expression levels of excision
repair cross-complementing 1 (ERCC1) and thymidylate synthetase (TYMS) in stageⅠto ⅢA non-small cell lung cancer(NSCLC)，and
their relationship with clinical and phathological characteristics of NSCLC patients.Methods:A total of 69 patients with stageⅠ to Ⅲ A
NSCLC from Thoracic Surgery of Air Force General Hospital are collected from June 2010 to October 2014. Lung cancer tissues were
obtained by intraoperative cut. KRAS mutations were detected with xTAGliquid chip technology (xTAG-LCT), and mRNA expression
levels of ERCC1 and TYMS genes were detected by branched DNA-liquidchip technology (bDNA-LCT).Results:Of 69 casess, 13 cases
were positive for KRAS mutations, the mutation rate was 18.8% (13/69). KRAS gene mutations in male patients had a higher detection
rate (29.3%, 12/41) than detection rate (3.6%，1/28) in female patients (P = 0.007). The mRNA expression levels of ERCC1 gene were
relevant to the pathological type, smoking，lymph node metastasis and clinical TNM stage. The mRNA expression levels of TYMS gene
were not relevant to clinical and phathological characteristics of NSCLC patients. The mRNA expression levels of ERCC1 gene in the
NSCLC patients with KRAS mutations were higher than those in patients with wild-type KRAS (P<0.05). KRAS mutations were not
relevant to the mRNA expression levels of TYMS gene.Conclusion:In stageⅠ to ⅢA NSCLC patients, KRAS mutations are more
frequent in men. The patients with KRAS mutations may not benefit from platinum-based chemotherapy.This will help us guide
individualized treatment in the early and mid NSCLC patients with operation. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
